Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
JNJ-79635322 by Johnson & Johnson for Refractory Multiple Myeloma: Likelihood of Approval
JNJ-79635322 is under clinical development by Johnson & Johnson and currently in Phase I for Refractory Multiple Myeloma. According to...
JNJ-79635322 by Johnson & Johnson for Relapsed Multiple Myeloma: Likelihood of Approval
JNJ-79635322 is under clinical development by Johnson & Johnson and currently in Phase I for Relapsed Multiple Myeloma. According to...
JNJ-79635322 by Johnson & Johnson for Primary Systemic Amyloidosis: Likelihood of Approval
JNJ-79635322 is under clinical development by Johnson & Johnson and currently in Phase I for Primary Systemic Amyloidosis. According to...